📍PRODIGE 44 - Preoperative modified PANDAS FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the PANDAS/PRODIGE 44 phase II randomized clinical trial. #ESMO24 OncoAlert

Result;NEGATIVE Chemotherapy followed by chemoradiation(CRT) in pancreatic cancer did not increase PFS or OS,nor did it reduce local or distant recurrence in patients with borderline resectable pancreatic cancer, when compared to neoadjuvant chemotherapy alone.#ESMO24 OncoAlert

I was interviewed by Eoin O’Carroll of ONCOassist at #ESMO2024 I outlined patient benefits from oncology treatment innovations & supportive care. Proud to share insights on incredible impact & commitment of my colleagues Irish Cancer Society via our services, research & advocacy. 💛

Dear Colleagues, A HUGE THANKS to all who made the #OncoAlert5k , Huge Thanks to Bayer for Supporting 5 NEW Catalyst Fellowships for Colleagues at LMIC's and NEXT One in #SABCS24 in OncoAlert 's Home Town of San Antonio Texas‼️ WE ARE ALL ONCOALERT #OncoAlertAF Gil Morgan, MD

Exciting connections and new faces at #ESMO24! A big thank you to everyone who visited the ONCOassist booth. Looking forward to seeing you all next year at #ESMO25.

💫 #ESMO24 Day 4 Roundup 💫 🌟 Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 👉 Phase 2 updated results for zanidatamab in HER2-positive mGEA included a

💫 #ESMO24 Day 4 Roundup 💫 🌟 Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 👉 The recommended Phase 2 dose for givastomig was determined to be 8-12

💫 #ESMO24 Day 4 Roundup 💫 🌟 Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC 🔗 buff.ly/4e2x707 #OncEd #OncoAlert

ONCOnews: Patritumab deruxtecan meets primary endpoint in metastatic EGFR mutant NSCLC merck.com/news/patrituma…

💫 #ESMO24 Day 4 Roundup 💫 🌟 Results from the multicenter double-blind randomized phase III SOLARIS trial (Alliance A021703) showed that the addition of high-dose vitamin D3 to standard treatment did not improve progression-free survival vs standard-dose vitamin D3 in patients

💫 #ESMO24 Day 4 Roundup 💫 🌟 Novel Antibody-Drug Conjugate Puxitatug Samrotecan May Demonstrate Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial 👉 Phase II expansion cohorts are ongoing in ovarian cancer, breast cancer, endometrial cancer, and

💫 #ONCOnews Roundup 💫 🌟 Daiichi Sankyo and Merck’s patritumab deruxtecan demonstrates a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI treatment 🔗

💫 #ESMO24 News Roundup 💫 🌟 Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress 👉 This Phase 1 study was conducted to evaluate the

💫 #ONCOnews Roundup 💫 🌟 FDA approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). 👉 Efficacy was investigated in KEYNOTE-483 (NCT02784171) 🔗

💫 #ONCOnews Roundup 💫 🌟 BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy 🔗 buff.ly/4gujmZp #OncEd #OncoAlert

💫 #ONCOnews Roundup 💫 🌟 FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer 👉 Late-breaking NATALEE data recently presented at ESMO provides additional confidence, with deepening of invasive disease-free survival benefit

🎉 Exciting news! EACCME® now accredits #IUCS24 🎓 Enhance your learning and register for free today! 👉 #urology #cancer International Urology Cancer Summit ONCOassist® | The go-to oncology app Giuseppe Banna Ravindran Kanesvaran

💫 #ONCOnews 💫 🌟 Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial 👉 Combining atezolizumab with CT and maintenance niraparib for late-relapsing

💫🌟📊 The HERO trial reaffirmed the inclusion of adult patients with prostate cancer, requiring at least 1 year of ADT, testosterone ≥150, and a PSA >2 if no prior local therapy. OncoAlert UroToday.com 🔹️The study spanned across diverse subgroups, showing relugolix superior to